27 results on '"Fic M"'
Search Results
2. Hepatitis C virus 5′ untranslated region variability correlates with treatment outcome
- Author
-
Bukowska-Ośko, I., Radkowski, M., Pawełczyk, A., Rosinska, M., Cortés, Caraballo K., Płoski, R., Berak, H., Horban, A., Stanczak, J., Fic, M., and Laskus, T.
- Published
- 2014
- Full Text
- View/download PDF
3. Corrigendum to: Hepatitis C virus (HCV) infection of peripheral blood mononuclear cells in patients with type II cryoglobulinemia. Hum Immunol. 2013;74(12):1559-62
- Author
-
Jabłońska, J., primary, Ząbek, J., additional, Pawełczyk, A., additional, Kubisa, N., additional, Fic, M., additional, Laskus, T., additional, and Radkowski, M., additional
- Published
- 2017
- Full Text
- View/download PDF
4. Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY registry
- Author
-
Fauchier, L., Greenlaw, N., Ferrari, R., Ford, I., Fox, K. M., Tardif, J. -C., Tendera, M., Steg, P. G., Sokn, F. J., Reid, C., Lang, I., Van den Branden, F., Cesar, L. M., Mattos, M. A., Nazar Luqman, H., Goudev, A., Dorian, P., Hu, D., Widimsky, P., Hassager, C., Danchin, N., Kaab, S., Vardas, P., Sulaiman, K. J., Al Mahmeed, W., Al Suwaidi, J., Al Rashdan, I., Abdulkader, F., Merkely, B., Kaul, U., Daly, K., Tavazzi, L., Jang, Y., Erglis, A., Laucevicius, A., Jamaluddin, A. N., Gamba, M. A., Tulevski, I. I., Stepinska, J., Morais, J., Macarie, C., Oganov, R., Shalnova, S., Al-Zaibag, M., Hou, M. K., Kamensky, G., Fras, Z., Kanic, V., Naidoo, D. P., Zamorano, J. L., Rickli, H., Jaussi, A., Sriratanasathavorn, C., Kalra, P., Lutai, M., Oleksandr, Nguyen, L. V., Henry, R., Ahuad Guerrero, A., Basara, M., Belcastro, F., Bertarini, J. A., Cazenave, C., Dreycopp, H., Egido, J., Estrella, J., Garofalo, D., Giordano, J., Lagioia, H., Lago, N., La Greca, R., Lema, L., Lopez Cabanillas, N., Luquez, H., Miller, C., Prada, E., Rodenas, P., Schena, R. G., Suarez, G., Tomatti, A., Colquhoun, D. M., Conradie, A., Cox, S., Cross, D., Fathi, R., Fitzgerald, B., Hamilton-Craig, I., Holt, G., Jayasinghe, S. R., Mai, N., Moolman, J., Motyer, R. A., Phillips, K., Rafter, A., Rahman, A., Rainbird, A., Scalia, G., Taylor, A., West, P., Alford, K., Amor, R., Astridge, P., Bastian, B., Bates, F., Doohan, M. M., Du Plooy, J., Ford, J. C., Kanagaratnam, L., Khoury, V., Parkin, R., Rogers, J., Sceats, G., Waldman, A., Wang, D., Wright, S., Ardill, J., Aylward, P., Beltrame, J. F., Bradley, J., Heddle, W., Joseph, M., Rajendran, S., Varughese, S., Brice, E., Hockings, B., Janssen, J., Kozlowski, A., O'Shea, J., Playford, D. A., Woollard, K., Ajani, A., Barron, G., Better, N., Chan, B., Chan, R., Cotroneo, J., Counsell, J. T., Eccleston, D. S., Forge, B. H. R., Hamer, A., Horrigan, M., Jelinek, V. M. J., Lew, R., O'Donnell, D., Panetta, F., Sebastian, M., Soward, A., Srivastava, P., Strathmore, N. F., Sylivris, S., Szto, G., Veth, V., Yip, T., Badr-Eslam, R., Kleemann, L., Steurer, G., Morz-Proszowski, B., Auhser, F., Teleky, U., Sepp, G., Beinhauer, A., Kero, D., Lavicka, C., Perger, T., Hadjiivanov, V., Feldner-Busztin, M., Mika, R., Filip, W., Mahr, A., Toplak, J., Millauer, M. G., Haralambus, P., Walcher, K., Karner, K. H., Ziak, E., Painsipp, P., Frank, U., Suntinger, A., Gritsch, W., Bode, G., Herrmann, R., Raffelsberger, R., Topf, H., Moser, E., Fochterle, J., Honsig, T., Mayr, K., Mayr, H., Kaserbacher, R., Dzien, A., Galehr, E., Felbermayer, M., Schwarz, R., Amini, R., Appeltants, H., Ballet, A., Bar, J. -P., Beckers, J., Bergen, J. -M., Berkenboom, G., Bernard, X., Bouvy, T., Briki, R., Claeys, M., Dascotte, Y., Davin, L., De Backer, T., De Keyser, F., De Meester, A., De Ridder, S., Dendale, P., Denef, K., Dhondt, E., Emonts, M., Geraedts, J. T. M., Goethals, M., Gregoire, J. -M., Haine, E., Herbots, T., Hoffer, E., Hutse, W. H. J., Kassab, A., Lafontaine, P., Lancellotti, P., Lefebvre, P., Lesseliers, H., Lozano, A., Maamar, R., Martinez, C., Noel, J. -F., Odent, G., Pasquet, A., Peperstraete, B., Purnode, P., Rogowsky, A., Rosseel, M., Salembier, J. -P., Surmont, P., Thermol, P., Vandeplas, A. M. F., Van de Walle, S., Vandergoten, P., Vanhauwaert, B. G., Vanneste, L., Vercammen, J., Verleyen, D., Vermander, D., Vervoort, G., Weytjens, C., Yanni, N., da Costa Pereira, A., Rocha de Lorenzo, A., Felice Castro Issa, A., Mahler Mioto, B., de Brito Vianna, C., Segre, C. A. W., Grupi, C. J., Okawabata, C., Favarato, D., Giusti Rossi, E., Fernandes, F., Pitella, F., Alvarez Ramires, F. J., Henpin Yue Cesena, F., Monteiro Ferreira, J. F., Junior, J. F., Tonet, L., Nastari, L., Machado Cesar, L., Gowdak, L. H., Matos, M. A., Moretti, M., Morgado, P. C., Vicente Amato, R., Tadeu Munhoz, R., Coimbra, S. R., Luqman, H. N., Yakovova, S., Mantcheva, M., Mincheva, V., Baurenski, L., Karastanev, K., Yordanova, V., Peneva, Y., Bailey, A., Wong, P., Fagan, M., Sabe-Affaki, G., Villasenor, F. M., Belisle, P., Son, W. K., Manyari, D. E., Giacomantonio, N., Lubelsky, B. J., Ezekiel, D., Leong, J. C. S., Grover, A., Vavougios, J., Pesant, Y., Kushner, A. M., Yeung, M. M. M., Vertes, G. E., Nasser-Sharif, F. J., Abdulla, A. H. K., Spensieri, D., Roy, A., Nguyen, T. T., Leclair, M., Morra, P., Everton Biglow, C., Baril, J. F., Lai, K., Wong, D. S., Martinho, V., Antoniadis, G. A., Searles, G. R., Rouse, D., Brisson, G., King Wong, S., Collette, R. S., M. S. C., Ho, Constance, C., Gendreau, R., Kellam, G. W., Cieza Lara, T. A., Boyrazian, H. A., Shamsuzzaman, M., Spink, D. R., Wong, A. P. T., Grewal, R. S., Che, C., Janes, J., Hechtenthal, N., Czarnecka, M., Saulnier, D., Levesque, G., Clavette, P. F., Kennedy, D. R., Kokis, A., Orenstein-Lyall, T. L., Shekhar Pandey, A., Robb, J., Verret, G., Czarnecki, W., Tsui, W. W. H., Perreault, F., Chouinard, G., Lafrance, G., Fullerton, G. M., Lavoie, J. P., Le Bouthillier, P., Tran, Q. H., Rodriguez Marrero, I., Ramadan, F. B., Talbot, P., Fazil, M. A., Cha, J. Y. -M., Garg, S., Chehayeb, R., Roy, B., Chan, Y. K., Harlos, H. E., Matheson, H. B., Patel, R., Vaz, G. F., Bhatt, J. S., Liu, E., Ashton, T. H., Sullivan, H., Quinn, L. P., Yared, K., Gupta, A., Sullivan, B., Campbell, J., Pallie, S., Kim, H., Vizel, S., Savard, D., Cherry, J. M., Gold, J., Chiu, S., Brouillette, G., Singh, R. R., Varma, S., Belanger, A., Myburgh, J. L., Berlingieri, J., Nisker, W., Boutros, G., Bakbak, A. I., Healley, W., Lasalle, L., Liu, F., Tu, C., Lv, S., Liu, X., Gao, H., Li, H., Zhao, H., Cao, L., Zhao, S., Wang, Y., Wu, D., Gu, F., Pan, G., Liu, P., Wang, X., Jiang, H., Li, J., Wang, J., Zhang, L., Ke, Y., Li, D., Chen, G., Xue, H., Jin, Q., Dong, W., Chen, Y., Fu, Z., Hu, H., Liang, Q., Yang, X., Zhou, Z., Xu, Z., Shao, C., Zhang, H., Pei, H., Song, L., Yu, M., Guan, T., Tang, Y., Wu, Y., Yang, M., Ceng, Q., Chen, X., Lin, L., Peng, Y., Yan, X., Yao, E., Zheng, X., Chen, B., Chen, H., Chen, W., Wang, R., Zheng, Y., Tan, H., Zhou, S., Zhou, Y., Liu, Z., Lu, Q., Lai, L., Pan, J., Wang, L., Fu, Q., Peng, J., Du, N., Lv, Y., Miao, W., Wang, H., Pu, Y., Wang, T., Dong, M., Gong, L., Zhang, J., Chen, Z., Jiang, Q., Ma, F., Xu, W., Dai, M., Wu, J., Yu, X., Chen, C., Huo, Y., Sun, L., Gao, W., Li, Z., Hu, Y., Chen, M., Li, G., Xue, M., Yao, Y., Pan, X., Sang, Z., Zhao, G., Hang, J., Ma, S., Zhang, G., Zhou, G., Li, W., Zhu, B., Yu, B., Zhu, S., Mao, J., Xu, M., Liu, Q., Huang, Q., Xie, Y., Feng, L., Chen, F., Chen, L., Liu, Y., Pei, X., Sun, A., Tian, Z., Wang, W., Yang, H., Yu, A., Zhang, M., Zhang, C., Guan, X., Zhou, X., Li, Y., Xing, Y., Chen, K., Luo, L., Dong, S., Zhang, Y., Ai, F., Xiong, C., Yang, F., Yang, K., Yan, J., Zhu, M., Zhang, A., Shan, G., Chen, J., Guo, J., Wu, S., Li, L., Liu, R., Yang, Y., Gao, X., Du, Z., Liang, L., Zhao, Y., Qian, J., He, L., Xiong, L., Chen, P., Peng, C., Zhu, J., Liu, J., Xie, X., Jiang, F., Li, A., Yang, Q., Cong, H., Guo, Y., Ren, N., Xiao, J., Zhao, R., Jiang, J., Deng, X., Wang, S., Wu, K., Zhang, X., Du, W., Shuang, D., Wei, J., Yuan, C., Li, F., Ou, X., Ou, Y., Yu, G., Zhang, S., Gao, J., Qian, Z., Wu, G., Zheng, S., Xu, D., Xie, J., Ren, W., Yao, X., Cai, B., Lv, J., Dong, J., Deng, Z., Bozkova, J., Carda, J., Dedkova, S., Dufka, A., Fridrich, J., Hodac, T., Jirmar, R., Kadleckova, A., Karlicek, M., Krupicka, J., Kuchar, J., Lavicka, V., Leso, J., Lorenc, Z., Micko, M., Navratil, P., Petrova, I., Povolna, P., Raisova, L., Raska, P., Ravlyk, V., Schlesingerova, S., Smrckova, E., Sternthal, P., Stursova, H., Vymetal, P., Zaoral, L., Wiggers, P., Markenvard, J., Andersen, L. K., Frost, L., Refsgaard, J., Strange, S., Egstrup, K., Sykulski, R., Hildebrant, P., Haghfelt, T., Ege, M., Cattan, S., Adam-Blanpain, M., Adda, M., Aimouch, N., Ardouin, L., Assouline, S., Aumjaud, A., Barjhoux, C., Baroudi, R., Beaurain, C., Bennouna, M. A., Bernard, A., Bernardeau, C., Blanc, E., Blum-Decary, I., Bodur, G., Boesch, C., Bonal, J., Bonhomme, R., Bonnet, J. L., Bories, J., Bourachot, M. L., Brumelot, F., Brunehaut Petaut, M., Brunschwig, C., Buffet, P., Calmettes, P., Centa, I., Chartier, B., Chemin, P., Chometon, F., Cohen, J., Colin, R., Cottin, Y., Crespo, F., Dabboura, A., David, F., Dehayes, P., Dematteo, P., Dibon, O., Dodemant, P., Dormagen, V., Dreyfus, X., Dubois, J. M., Duclos, F., Ducoudre, M., Duprez, O., Durand, P., Durand, E., Egloff, P., Escande, M., Escourrou Berdou, M. C., Esna Ashari, G., Feldmann, I., Ferrieres, J., Foltzer, E., Fontanet, B., Garandeau, M., Garban, T., Geffroy, S., Gillet, T., Godart, S., Gosse, P., Gratia, P., Greiner, O., Gueusquin, A., Guiu, E., Guy, J. M., Haddad, S., Hennebelle, V., Honorat, S., Hourany, A., Hua, G., Jacquier, P., Jean, S., Jeremiasz, R., Kohler, P., Lacroix, A., Leandri, M., Lemiere, Y., Liautard, M., Loheac, P., Louchart, J. C., Magnus, P., Maheu, B., Malaterre, H. R., Manchet, G., Mantoux, J., Manzi, D., Marachli, M., Maroun, M., Meneveau, N., Messas, E., Mougeolle, J. L., Mouhat, T., Muller, J. J., Naisseh, M., Nocon, P., Onger, D., Ouguoujil, A., Ovize, M., Page, E., Pareathumby, K., Pleskof, A., Poinson, P., Pons, G., Pouderou, P., Poujois, J. N., Probst, V., Prunier, F., Prunier, L., Puel, V., Rechtman, D., Rennert, R., Rijavec, B., Riou, Y., Robert, J., Roche, C., Roul, G., Salaun, B., Saleh, B., Sandalian, A., Sander, M., Schenowitz, A., Silvestre, A., Soleille, H., Tabet, S., Tardy, M., Thomas-Richard, F., Truong, B., Varaldi, J., Vial, H., Walch, J. M., Wazana, M., Zeitouni, R., Audibert, H., Alizon, F., Amlaiky, A., Asplanato, M., Baranes, C., Bariaud, M., Bernasconi, F., Bousquet, P., Ceraulo, C., De Geeter, G., Donetti, J., Doucet, B., Doucet, J., Dutoya, T., Ennouchi, D., Fallacher, M. H., Fouquet, G., Fourchard, V., Gdalia, J., Grollier, G., Guerard, S., Jeannerat, P. A., Jobic, Y., Joulie, V., Jourdain, P., Jouve, V., Ketelers, R., Khaznadar, G., Kohan, P., Koujan, B., Lammens, B., Landragin, I., Le Moal, E., M'Bey, D., Maes, F., Maheas Morlet, S., Massabie, R., Meddah, D., Meriaux, F. X., Mestre-Fernandes, C., Meyssonnier, P., Migliore, M., Milewski, J., Millet, J. F., Mingam, S., Nazeyrollas, P., Paganelli, F., Pellerin, F., Petitjean, F., Pinzani, A., Pladys, A., Primot, P., Pucheu, A., Rahali, A., Ravoala, P., Rousson, D., Samama, P., Sardon, M., Silvestri, R., Soskin, P., Tabone, X., Tricot, C., Vaquette, B., Vogel, M., Weingrod, M., Aboyans, V., Amoretti, R., Aubry, J., Berthezene, P., Binet, D., Bonnaud, X., Bonnet, P., Bonny, A., Bouchaya, T., Boureux, C., Bourgeois, J. M., Brottier, L., Cavert, B., Cleron, S., Dechoux, E., Delhomme, C., Detienne, J. P., Dubs, J. P., Faudon, B., Fellous, F., Fressonnet, R., Garaud, Y., Garcia, D., Geneves, M., Gleizes, J. L., Guyetand, C., Hermellin, B., Iovescu, D., Kanner, J. P., Khanoyan, P., Leherissier, A., Maximovitch, A., Merian, B., Messali, P., Moreau, Y., Moyal, J., Payot, L., Petoin Peuch, L., Prevot, J. L., Raymond, P., Relange, D., Reymond, S., Robert, J. F., Rosenstein, H., Schneider, J., Schultz, R., Tanielian, P., Thoin, F., Thomas, L., Touzet, P., Steg, G., Amiel Oster Sauvinet, G., Baylac Domengetroy, F., Chamou, K., Etcheverry, B., Farges, J. L., Fraboulet, J. Y., Goralski, M., Janody, D., Mamez, B., Manlay, W., Paillard, F., Pelier, F., Petit, A., Skonieczny, M., Augarde, R., Fournier, J. B., Liandrat, S., Lim, P., Noury, A. I., Paris, D., Saade, M., Stordeur, J. M., Pornin, M., Galinier, M., Balice-Pasquinelli, M. A., Sosner, P., Yvorra, S., Delcoulx, E., Mouquet, F., Poulard, J. E., Sudre, A., Heno, P., Biausque, F., Guenoun, M., Attia, G., Pouwels, S., Carpentier, L., Verbrugge, E., Ziccarelli, C., Elkohen, M., Tricoire, J., Lang, P., Huttin, O., Altevogt, B. -M., Altmann, U., Baar, M., Berrisch-Rahmel, S., Birkenhagen, A., Blase, I., Blindt, R., Bosch, R., Brattstrom, A., Breuer, H. -H., Castrucci, M., Cicek-Hartvig, S., Cierpka, R., Claus, M., Deissner, M., Drexler, M., Eggeling, T., Eisele, G., Enayat, D., Frickel, S., Gessner, S., Giokoglu, K., Gmehling, J., Goss, F., Grooterhorst, P., Gysan, D. B., Haberl, R., Haerer, W., Hassler jun, N., Heinemann, S., Henschel, F., Hinrichsen, M., Hofer, W., Hofmeister, A., Hoh, G., Horstkotte, E., Jager, F., Jeserich, M., Keil, U., Killat, H., Kimmel, S., Kindel, M., Kindler, P., Kleta, S., Konemann, J., Konig, K., Krause-Allmendinger, H., Kronberg, K., Kruck, I., Mannl, V., Meinel, A., Mentz, G., Meyer-Michael, E., Mibach, F., Moller, S., Muth, S., Nelbock-Huber, E., Ohlmeyer, D., Ozkan-Rashed, Z., Paulus, C. -P., Perings, S., Placke, J., Raters, C., Reifart, N., Rink, A., Rybak, K., Salecker, I., Schermaul, K. -H., Schmidt, E., Schmitz, K. -H., Schon, N., Schroder, T., Sievers, B., Simon, M., Spengler, U., Speth-Nitschke, M., Stumpp, A., Szabo, S., Taggeselle, J., Tamm, A., Thelemann, A., Thelemann, C., Thummel, H., Unger, G., Utech, A., Volmar, J., Wauer, B., Wehr, G., Weinrich, L., Weinrich, R., Windstetter, U., Wirtz, J. H., Wittlich, N., Ziehn, P., Zundorf, P., Al Wahshi, Y., Singh, P. P., Narayan, A., Al Tamimi, F., Al Yazeedi, J., Ayche, M., Al Lawati, A., Al Dhanki, M., Salustri, A., Al Sousi, A., Salah, T., Tamimi, M. Y., Agrawal, A., Wassef, A., Baslaib, F., Al Radaideh, G., Yusufali, A., Bazargani, N., Akbar, M., Abdel Wahab, H., Abdel Malak, S., Ghaly, I., Al Ghool, S., Al Kandari, F., Haiba, M., Alanbaei, M., El Menyar, A., Gomaa, M. M., Khalifa, A., Garadah, T., Avgerinos, C., Gouli, O., Stergiou, D., Alexopoulos, I., Pappas, C., Petropoulos, I., Chatzioakim, G., Pontikakis, N., Priftis, C., Mpompoth, P., Bourazanis, I., Papathanasioy, A., Avlonitis, S., Zakopoulos, C., Koutsimpanis, G., Tsamopoulos, I., Christoforidis, C., Zachos, V., Kalaras, P., Karachaliou, M., Liatas, C., Pournaras, G., Theodorakis, G., Orestis, I., Panisois, K., Chalkiadakis, E., Arfaras, V., Melainis, Kolios, G., Boutsikos, P., Kotsalos, A., Mitropoulos, D., Samothrakitis, A., Svolis, K., Anastasiou, E., Gkinis, T., Dalampyras, P., Kalampalikis, A., Leontaridis, I., Gabriilidis, S., Konstantinidis, I., Plastiras, V., Tarenidis, P., Marozsan, I., Edes, I., Czuriga, I., Cziraki, A., Toth, K., Dongo, A., Turi, P., Forster, T., Borbola, J., Bachmann, B., Masszi, G., Orban, M., Gerges, G., Balogh, G., Bajcsi, E., Sereg, M., Dezsi, C. A., Takacs, I., Nagy, L., Kisjos, B., Janosi, A., Nagy, A., Nagy, K., Buttl, A., Lippai, J., Sziegl, Z., Malkocs, Z., Foldi, A., Fikker, K., Szabo, E., Gupta, R., Natarajan, S., Dalal, J., Saran, R. K., Mehta, A., Samal, M. P., Khan, I. A., Ghose, T., Sawhney, J. P. S., Roy, T., Chandra, S., Modi, S., Singh, M. M., Vijayaraghavan, G., Sreenivasa Murthy, L., Ramesh, S. S., Dayasagar Rao, V., Chenniappan, M. S., Vadavi, A., Kunhali, K., Srinivasa Reddy, K., Thillai Vallal, S., Khera, P., Dasbiswas, A., Ganguly, K., Chatterjee, S. S., Prasad, B., Shukla, D., Trivedi, A. K., Ahuja, R., Deb, J., Rawal, J., Karnik, R., Hiremath, M. S., Kumbla, D. K., Shetty, S. R., Chonkar, N. S., Juneja, L. M., Goyal, B. K., Sheahan, R., Mulvihill, N., Vaughan, C., Fleming, S., Shiels, P., Keelan, P., Kiernan, T., Cosgrave, J., Day, B., Kelly, K., MacNamara, F., Maguire, B., Clifford, A., O'Gara, A., Guardigli, G., Riccioni, G., Pedretti, R., Felis, S., Pernice, V., Lillo, A., Gori, P., Zaca, F., Giacomazzi, F., Terrosu, P., Cernetti, C., Antonicelli, R., Ansalone, G., Balbi, M., Tamburino, C., Tantillo, S., Proietti, F., Mallamaci, V., d'Este, D., Silvestri, F., Magliari, F., Capuano, N., Marchionni, N., Turiel, M., Maxia, P., Marullo, L., Vicentini, A., Pes, G., Caridi, G., Grieco, A., Doronzo, B., Lacche, A., Massari, F., Orazi, S., Antonelli, G., Provvidenza, M., Nicolino, A., Servi, S. D., Sinicropi, G., Maragoni, G., Azzolini, P., Brscic, E., Bongo, A. S., Perna, G., Perna, B., La Rosa, C., Mossuti, E., Ferrante, R., Petrillo, M. E., Castellari, M., Di Pasquale, P., Saporito, F., Alitto, F., Testa, R., Kang, S. M., Koo, B. K., Hong, S. K., Kim, W., Lee, S. H., Seo, H. S., Gwon, H. C., Kang, D. H., Kwon, H. M., Chae, I. H., S. J., Oh, Shin, J. H., Goh, C. W., J. H., Zo, Hong, T. J., Kim, D. S., Cha, T. J., Ryu, J. K., Kim, Y. J., Hwang, J. Y., Hur, S. H., Jeong, M. H., S. K., Oh, Jin, D. K., Jung, K. T., Rhew, J. Y., Lee, S., Jeon, D. W., Kim, S. H., Mintale, I., Latkovskis, G., Hansone, S., Rozkova, N., Baika, A., Jasinkevica, I., Abele, S., Laizane, I., Pontaga, N., Ecina, V., Mihailova, I., Kondratovica, A., Jurgaitiene, R., Slapikas, R., Barauskiene, G., Jankauskiene, E., Reviene, S., Vaisvila, T., Zaronskiene, D., Slapikiene, O. B., Kupstyte, N., Rinkuniene, E., Steponeniene, R., Kojeliene, J., Badariene, J., Dzenkeviciute, V., Sadauskiene, E., Butkuviene, I., Stankevicius, R., Paliulioniene, R., Snikyte, R., Mazutavicius, R., Abdul Rahim, A. A., Mohamed Yusof, A. K., Chee, K. H., Sadiq, A., Ramanaidu, S., Sim, K. H., Ong, T. K., Fong, A. Y. Y., Chang, B. C., Chua, S. K., Cham, Y. L., Moh, d. Amin N. A., Tan, S. K., Chandran, K., Cheah, Y. W., Sinnadurai, J., Choor, C. K., Sia, K. K., Ang, C. C., Singh, J., AbdulWahab, M. Z., Ghapar, A. K., Muthu, A., Kauthaman, M., Jaafar, A. H., K. H., Ng, Tahir, A. R., Abdul Manap, H., Ch'ng, B. S. K., Ch'ng, E. T., Ismail, O., Sahar, A. S., Abdul Kareem, B. B., S. K., Ma, Liew, H. B., Bhaskaran, R. K. M., Shah, R. P., Joseph, K. L., Noor Hasni, H., W. K., Ng, Choo, G. H., Yeo, C. K., Lai, V. M., Lai, Y. C., Tay, M. H., Lim, B. A., Esperon, G. L., de Jeus Zuniga Sedano y America Alvarez, J., Azar Manzur, F., Jerjes Sanchez, C., Cerda Rojas, J., Carrillo Calvillo, J., Petersen Aranguren, F., Martinez Sanchez, C., Vieyra, G., Gonzalez Romero, S., Puente Barragan, A., Redding Escalante, F., Chavez Paez, J., Fernandez Valadez, E., Gaxiola, E., Manautou, L. E., Henne Otero, O., Barrera Bustillos, M., Leyva Pons, J. L., Gomez Alvarez, E., Romo Santana, J. R., Martinez Redding, J., Arias Mendoza, A., Rodriguez Briones, I., de Jeus Rivera Arellano, J., Arenas Leon, J. L., Alcocer Gamba, M., Alexanderson, E., Ruiz Esparza, M. E., Elizondo Sifuentes, L. A., Briseno, J. L., Sandoval, S., Castro, A., Cue Carpio, R., Rodriguez, E., Rojas, G., Solache, G., Diaz, R., Baleon, R., Ferreyra Solorio, C., Alberto Ramirez Reyes, H., Lopez Martinez, M., Romero Maldonado, M. A., Escobedo de la Pena, J., Hilario Jimenez Orozco, J., Reyes Cisneros, F. A., Alvarez Gil, J., Bautista, G., Lopez, Odin de los Rios Ibarra, M., Somsen, G. A., Wittekoek, J. E., Miedema, K., de Sauvage Nolting, P. R. W., Chlewicka, I., Brodzicki, P., Stasiuk, T., Szalkowski, P., Kulig, W., Maliszewski, M., Krolicka, K., Zdrojewska, J., Nikodemska, I., Szpak, A., Wrebiak-Trznadel, M., Prokop, A., Szulc, M., Olszewski, A., Kepa, W., Banach, J., Weglarz, M., Galuszka-Bilinska, A., Krolak, A., Cisowska-Drozd, E., Orzechowski, K., Jezewska, M., Adamaszek, K., Glanowska, G., Pitsch, T., Matuszewska, G., Nowowiejska-Wiewiora, A., Deren, M., Walawski, G., Soltysiak, M., Wysocki, R., Jarosinski, G., Drzewiecka, A., Lugowski, T., Jankowska, A., Blaszczak, P., Drozd, J., Lotocka, E., Duchowska, R., Sobczyk, D., Jarmuzek, P., Sidor, M., Adamczyk-Kot, D., Sudnik, J., Cygler, J., Skoczylas, I., Poprawa, B., Kisiel, L., Kossowska, U., Sikorska-Buczkowska, B., Modzelewska, K., Demianiuk, B., Streb, W., Mularek-Kubzdela, T., Bogdanski, P., Kazmierczak, E., Zimolag, R., Lorenc, J., Furtak, R., Regulska, A., Winter, M., Fic, M., Turek, P., Nowicka, E., Bryl, W., Lenartowska, L., Jerzykowska, O., Mackow, M., Gadzinski, W., Kacorzyk, R., Zalewska, D., Sadlowski, R., Slaboszewska, J., Gruchala, M., Frankiewicz, A., Walczewska, J., Adamkiewicz-Piejko, A., Chyrek, R., Jankowska, L., Correia, A., Girao, A., Herdade, A., Sequeira, A., Tavares E Taveira, A., Gonzaga, A., Ribeiro, A., Albuquerque, A., Fernandes, A., Estriga, A., Rocha De Almeida, A., Lourenco, A., Pereira, A., Faria, A., Carvalho De Moura, B., Camossa, C., Alves, C., Aguiar, C., Rodrigues, C., Wellenkamp, E., Lins, E., Fernandes De Sousa, F., Moreira Pinto, F., Matias, F., Silva Alves, G., Braganca, G., Proenca, G., Pego, G., Vinhas, H., Arroja, I., Rosa Pais, J., Silva E Sa, J., Vasconcelos, J., Matos, J., Freitas, J., Ferreira, J., Costa, J., Alcaravela, J., Mimoso, J., Antunes, J., Ferreira Dos Santos, J., Nobre Dos santos, J., Tito Martins, J., Fernandes, J., Chambel De Aguiar, J., Moreira, J., Carvalho, J., Forte De Carvalho, J., Calaca, J., Simoes, L., Lopes Antunes, L., Soares, L., Semedo, L., Macedo, L., Sargento, L., Basto, L., Carpinteiro, L., Rebelo, L., Oliveira, L., Catarino Carvalho, M., Alves Costa, M., Gamboa, M. C., Ferrao E Vasconcelos, M. F., Custodio, M. H., Mendonca, M. I., Pinto Vaz, M. J., Espiga De Macedo, M., Lazaro, M., Martins Oliveira, M., Pelicano, N., Lousada, N., Rodrigues, O., Matos Dias, P., Fonseca, P. F., Ferreira, P., Abreu, P. E., Monteiro, P., Seabra Gomes, R., Carvalho, R., Santos, R., Pires Pereira, R., Rosado Soares, R., Baptista, S., Reis Monteiro, S., Gil, V., Sanfins, V., Martins, V., Anghel, M., Arsenescu Georgescu, C., Babes, K., Banu, M., Beyer, R., Bratu, I., Bumbu, A., Capalneanu, R., Chioncel, O. D., Chiscaneanu, T., Christodorescu, R., Cindea Nica, N., Cinteza, M., Coman, S., Constantinescu, M., Craiu, E., Dan, G. A., Dan, D. C., Dan, A., David, C. M., Dorobantu, M., Farcas, D., Firastrau, V., Florescu, C., Ghicu, A., Giuca, A., Grigoriu, R., Ionescu, D. A., Ionescu, D. D., Iosipescu, L. C., Ivan, M. V., Lighezan, D., Magheru, S., Magherusan, M., Marinescu, S. M., Motoc, A. C., Musetescu, R., Rau, M., Rotaru, L., Rus, H., Sirbu, O., Sorodoc, L., Spinu, C. M., Stanciulescu, G., Statescu, C., Toringhibel, M., Trambitas, R., Trocan, N., Tudose, A., Vinereanu, D., Zagreanu, M., Dymova, D., Semenova, N., Zherebtsova, A., Fedoskin, V., Gurianova, N., Bolotova, N., Knyazeva, V., Spitsina, T., Sytilina, N., Atamanchuk, N., Giorgadze, M., Zarechnova, S., Kutuzova, S., Sharapova, Y., Stelmakh, I., Sinyukova, O., Rostik, S., Evtukhova, L., Sukhanova, L., Makhieva, T., Tereshko, S., Kolesnikov, V., Kochurov, E., Marchenko, B., Nurgalieva, S., Galeeva, Z., Andreicheva, E., Zakirova, V., Baleeva, L., Minsafina, A., Borodina, N., Arkhipova, Y., Krechunova, T., Scherbak, M., Merkhi, A., Aksyutina, N., Ratovskaya, O., Suglobova, E., Kozhelenko, Y., Potapova, E., Poluyanova, G., Naberezhnova, N., Daniels, E., Atueva, K., Tsaryabina, L., Kurekhyan, A., Khishova, N., Dubinina, E., Demina, O., Mochkina, P., Bukanina, E., Tolpygina, S., Polyanskaya, Y., Malysheva, A., Kheliya, T., Serazhim, A., Voronina, V., Lukina, Y., Dubinskaya, R., Dmitrieva, N., Kuzyakina, M., Khartova, N., Bokuchava, N., Smirnova, E., Esenokova, A., Pavlova, Y., Smirnova, O., Astrakhantseva, P., Bykovskaya, S., Charikova, O., Berdnik, K., Karaseva, T., Zhabina, L., Oleinikova, N., Dzhkha, O., Grigoryan, S., Yakovenko, E., Ivaschenko, T., Kiseleva, I., Shokina, T., Novikova, M., Khodanov, A., Popova, L., Latyntseva, L., Kilaberiya, O., Makarenkova, K., Nosova, N., Gerasimova, T., Boikova, L., Sharapova, N., Kulikova, Y., Pasechnaya, N., Bulakhova, E., Kurochkina, S., Bratishko, I., Likhobabina, O., Panova, E., Voronina, N., Bizyaeva, N., Gusev, O., Nevolina, N., Arsentieva, T., Budanova, I., London, E., Melnikova, Khripun, A., Polyaeva, L., Osadchuk, E., Krasnoslobodskaya, O., Yakimova, N., Lugin, A., Sosnova, Y., Il'ina, E., Kositsina, G., Shanina, I., Kostomarova, S., Malgina, M., Omelchenko, M., Gorlova, I., Eidelman, S., Salakhova, A., Bondarenko, B., Sopia, R., Baboshina, N., Eliseeva, N., Tumarov, F., Petrochenko, N., Khudina, I., Arabadzhi, N., Samakhovets, V., Tkhorzhevskaya, L., Sinotova, T., Zherlitsyna, E., Minkin, S., Petrova, N., Tikhonov, Y., Shmakova, N., Abduvalieva, V., Kuzmicheva, M., Nikolaeva, L., Varezhnikova, O., Dmitrieva, T., Mikhailova, E., Yanina, Y., Kapustina, L., Vazhdaeva, Z., Golovina, G., Fedorova, N., Nikolaeva, I., Fillipova, O., Gareeva, L., Tuktarova, F., Khmelevskikh, N., Karnot, V., Golub, M., Surovtseva, I., Kulygina, V., Shelomova, N., Kruglova, I., Pokrovskaya, I., Rodina, O., Polkina, L., Biryukova, N., Filippova, E., Kotova, E., Ignatieva, T., Alekseeva, T., Gruznykh, L., Mozerova, E., Moksyuta, E., Kosachek, E., Srtumilenko, N., Baranova, O., Voronova, T., Bayakhchan, L., Grudtsina, I., Gorshkova, L., Shamsutdinova, O., Getman, M., Gorodilova, I., Karnaukhova, N., Rotenberger, V., Isaeva, L., Lebischak, G., Ryzhkova, V., Usoltseva, E., Mescharekova, D., Tavlueva, E., Mineeva, E., Stikhurova, M., Kosareva, L., Grechishkina, O., Nikishina, S., Ilyukhina, A., Gureeva, O., Soin, I., Erofeev, S., Lebedev, S., Kudryavtsev, L., Gamzatov, E., Maximchuk, N., Grekhova, L., Kolevatova, L., Kazakovtseva, M., Kolesova, O., Zharikova, L., Kukaleva, V., Starostina, N., Grushetskaya, I., Kazachkova, V., Pashentseva, I., Shimonenko, S., Sirazov, I., Chernozemova, A., Golubeva, O., Mingalaeva, S., Zatsarina, E., Kozlov, D., Davydova, N., Larina, O., Fayez Al-Habib, K., Al-Hersi, A., Al-Baker, H., Al-Faleh, H., Moberik, A., Radwan Arafah, M., Al-Shamiri, M., El-Shaer, F., Al Zaibag, M., Bdeir, M., Suliman, I., Mukhtar, A., Omar, H., Jamiel, A., Elkrail, A., Alanazy, M., Habab, M., Ashmak, K., Nourallah, R., Mak, K. H., Singh, B., Baldev, S., Chee, T. S., Koo, C. C., Low, L. P., Nair, V. P., K. S., Ng, Quek, S. S. S., Tan, E. H. M., A. L. R., Ng, Chuang, H. H., Kaliska, G., Murin, J., Hatalova, K., Gaspar, L., Simkova, I., Dubrava, J., Pjontek, J., Pella, D., Banikova, A., Szentivanyi, M., Kovar, F., Benacka, J., Gonos, I., Fazekas, F., Kycina, P., Poles, J., Pernat, A., Veternik, A., Cernic-Suligoj, N., Kerbev, M., Krajnc, I., Zagozen, P., Alam, A., Brown, B., Luke, B., Variava, E., Nethononda, R., Joubert, S., Matthews, P., Nkombua, L., Antia, V., Bhayat, J., George, S. K., Ranjith, N., Vawda, G. H. M., Govender, S., Soosiwala, I., Shein, K., Panajatovic, M., Flores, J., Khan, M. S. H., Blignaut, S., Coetzee, K., Burgess, L., Freeman, V., Theron, H. D., Arnau Vives, M. A., Abardia Oliva, F. J., Albero Martinez, V., Alegret Colomer, J. M., Alegria Ezquerra, E., Almeida Fernandez, C. A., Alvarenga Recalde, N., Alvarez Aunon, A., Alvarez Garcia, P., Amo Fernandez, C., Amoros Galito, C., Ancin Viguiristi, R., Antona Makoshi, J., Aparici Feal, M., Ardiaca Capell, A., Arnedillo Pardo, J., Arquero Garcia, G., Arrarte Esteban, V., Baquero Alonso, M., Barahona Perez, P., Bardaji Mayor, J. L., Barriales Alvarez, V., Batalla Celorio, A., Bierge Valero, D., Blanco Castineiras, J., Bosa Ojeda, F., Botana Penas, C., Brufau Redondo, H., Bruguera Cortada, J., Cabau Rubies, J., Cabrera Sole, R., Calvo Iglesias, F., Cantabrana Miguel, S., Carrillo Cardoso, R., Casanovas Pie, M., Casas Gimenez, P., Castillo Luena, E., Castillo Moreno, J. A., Castillo Orive, M., Chirivella Gonzalez, A., Chopo Alcubilla, J. M., Climent Paya, V., Cobos Gil, M. A., Colomer Martin, J. L., Concepcion Clemente, A., Cortes Sanchez, R., Cremer Luengo, D., Darnes Soler, S., de Andres Novales, J., De Castro Aritmendiz, R., Delgado Prieto, J. L., Diaz Diaz, J. L., Escobar Cervantes, C., Ezcurdia Sasieta, J., Facila Rubio, L., Falces Salvador, C., Federico Zaragoza, P., Fernandez Alvarez, R., Fernandez de la Cigona, F., Fernandez Lazaro, L. A., Fernandez Leoz, L. C., Fernandez Mouzo, R., Fernandez-Valls Gomez, M., Ferreiro Rodriguez, B., Franco Aranda, C., Freire Corzo, J., Fuertes Alonso, J., Fuertes Beneitez, J., Galve Basilio, E., Garcia Garcia, C., Garcia Gonzalez, M. J., Garcia Ortego, S., Garcia Saavedra, V., Garcia-Moll Marimon, J., Gascuena Rubia, R., Gentille Lorente, D., Gervas Pavon, H., Gilabert Gomez, R., Gomez Barrado, J. J., Gomez Doblas, J. J., Gomez Martinez, M. J., Gonzalez Juanatey, C., Gonzalez Toda, V., Gonzalvez Ortega, M., Gordillo Higuero, E., Hernandez Afonso, J., Herrera Fernandez, D., Homs Espinach, E., Idoate Gastearena, A., Irurita Latasa, M., Izquierdo Gonzalez, R., Jaquet Herter, M., Lagares Carballo, M., Lastra Galan, J. A., Limeres Gonzalez, B., Lopez Aranda, M. A., Lopez Barreiro, L., Lopez Gomez, D., Lopez Granados, A., Lopez Mourino, V., Lopez-Sendon, J. L., Mainar Latorre, L., Marin Araez, E., Marin Ortuno, F., Martin Santana, A., Martinez Florez, J., Martinez Gonzalez, J., Martinez Rivero, J. F., Marzal Martin, D., Mazzanti Mignaqui, G. F., Melero Pita, A., Molina Laborda, E., Montero Gaspar, M. A., Mora Robles, J., Morales Gonzalez, J., Moreno Arribas, J., Moreno Casquete, M. T., Moro Lopez, J. A., Moya Lopez, C., Murga Eizagaechevarria, N., Narro Garcia, F., Navarro Manchon, J., Navas Navas, C., Novo Garcia, E., Nunez Gamero, J. A., Ordonez Espana, A., Ortiz de Murua Lopez, J. A., Orts Soler, E., Otero Chulian, E., Pastor Torres, L., Paule Sanchez, A. J., Paz Bermejo, M. A., Pena Perez, G., Perea Egido, J. A., Perez de Isla, L., Perez Ibiricu, S., Perez Martinez, M. A., Perez Paredes, M., Peris Domingo, E., Pinar Sopena, J., Pindado Rodriguez, C., Pinilla Lozano, M. J., Pinero Ramirez, C., Porras Ramos, Y., Ramos Ariznabarreta, F., Rayo Gutierrez, M., Roca Catalan, J. M., Rodriguez Almodovar, A., Rodriguez Collado, J., Rodriguez Fernandez, A., Rodriguez Fernandez, J. A., Rodriguez Hernandez, J. A., Rodriguez Tejero, I., Romeo Castillejo, I., Romero Alvira, D., Romero Hinojosa, J. A., Romero Menor, C., Rossi Sevillano, P., Rueda Calle, E. C., Rueda Soriano, J., Ruiz Perez, P., Sagastagoitia Gorostiza, T., Sainz Hidalgo, I., Sandin Rollan, M., Santaolalla Rodriguez, S., Santas Olmeda, E., Santos Iglesias, J. L., Sanz Rodriguez, M. L., Segura Laborda, I., Serrano Garcia, S., Sevilla Toral, B., Silva Melchor, L., Simarro Martin-Ambrioso, E., Sola Casado, R., Soriano Navarro, C., Soto Ruiz, M. I., Talavera Calle, P., Torres Diaz, P. L., Troncoso Gil, A., Trujillo Berraquero, F., Ulecia Martinez, M. A., Umaran Sanchez, J., Vaticon Herreros, C., Vazquez Garcia, A., Vega Barbado, J. L., Velasco Espejo-Saavedra, E., Vicente Vera, T., Vida Gutierrez, M., Villar Mariscal, C., Vives Bonato, G., Wu Amen, L., Yanes Bowden, G., Yanez Wonenburger, J. C., Zamorano Gomez, J. L., Zarauza Navarro, J., Monnier, P., Forclaz, A., Grobety, M., Schlueter, L., Vuille, C., Nacht, C. A., Evequoz, D., Ciaroni, S., Domine, F., Berube, J., Hellermann, J., Koller, R., Bourgeois, G., Engel, R., Niederberger, C., Stadler, P., Gnadinger, M., Schmied, C., Wettstein, T., Badorff, C., Hilti, P., Chetelat, C. A., Sepulcri, F., Brunner, H., Schindler, J., Kraus, M., Gmur, W., Bouranasompop, C., Jiraroj-ungkun, W., Lapanun, W., Vivekaphirat, V., Panpunnung, S., Dutsadeevettakul, S., Tasneeyapant, S., Ngamjanyaporn, P., Apitamsuntorn, S., Tantisiriwat, W., Suithichaiyakul, T., Kuanprasert, S., Wongcharoen, W., Phrommintikul, A., Musigchai, C., Chantrarat, T., Uerojanaungkul, P., Apinyasawat, S., Tangcharoen, T., Lertnantakul, M., Wasuwat, A., Harinasuta, J., See, O., Chaithiraphan, V., Boonyasirinant, T., Boonyapisit, W., Kittipovanonth, M., Buakhamsri, A., Piyayotai, D., Hutayanon, P., Junejo, S., Aiyegbayo, O., Ancliff, H., Bradshaw, C., Cervenak, R., Choi, H., George, E., Gilmour, I., Gough, D., Idrissi-Sbai, A., Ingham, J., Al-Khalidi, B., Liston, A., Mackrell, J., Pattison, I., Ramachandran, R., Ray, N., Reddy, G., Sen, I., Shetty, K., Singh, L., Stanley, M., Wallace, A., Weatherhead, M., Gilbert, T., McCansh, G., Higgins, S., Killeen, C., Cromarty, I., Franklin, P., Pinch, E., Dhesi, A., Dernedde, C., Lawrence, M., Simper, H., Noble, M., Dalton, G., Stevens, L., Berry, P., Hand, C., Oliver, R., Jones, H., Sampson, P., Taylor, N., Grogono, R., Dalrymple, J., Martin, A., Thurston, S., Elsby, K., Vallis, M., Morrison, G., Lang, C., Watson, A., Thomson, A., Dougall, H., La Hay, B., Compson, L., McCracken, A., Calder, J., Weber, F., Richmond, D., Brownlie, R., Brown, G., MacCowan, H., Heap, A., Perry, M., Holden, L. A., Scott, G., Haldane, N., Hood, S., Cullen, I., Bell, J., McNaught, P., Sharif, M., Dunn, J., Hay, D., Ross, S., Shaw, R., Hay, L., Langridge, S., Burns, R., Crawford, L., Kennedy, A., Logan, D., McAlavey, P., Brown, M., Costello, P., McLaren, G., Potter, A., McPherson, J., Drijfhout, M., Finlayson, J., Troup, D., Woodall, A., Pearce, J., Williams, S., Parkar, W., Yusuf, A., Benett, I., Bishop, P., Thomas, H., Caldwell, I., Ormiston, P., Kwok, S., Kanumilli, N., Saul, P., Milligan, H., Wilkinson, I., Vance, A., Paul, N., Paul, C., Shaikh, I., Ellis, R., Vites, N., Steeds, R., Goodwin, D., Aftab, A., Banham, S., Chauhan, N., Grocutt, M. S., Gupte, A., Jordan, R., Jheeta, B. S., Ladha, K., Nazir, M., Pal, R., Patel, R. P., McManus, R., Singal, A., Saunders, P., Syed, A. B., Bahal, A., Dau, H., Walker, D. M., McNeilly, R., Bolidai, A., MacCarthy, N., Lawton, D., Vardhani, M., Sengupta, G., Kinloch, D., Howie, F., Serrano-Garcia, A., Paget, S. E., Till, R., Seal, P., Morrell, J., Maxwell, T., Singh, G., Warden, D., Elias, R., Dixon, C., Pandey, R. K., Challenor, V., Davies, S., Gibbs, M., Gillet, A., Goldie, C., Jarvis, I., Johnson, P., Malden, M., Moore, J., Morton, C., Nehrig, K., Sheringham, P., Wilson, G., Halcox, J., O'Connor, I., Ling, K., Edwards, D., Charles, H., Weatherup, A., Davies, E., Watkins, N., Morgan, D., Davies, R., Lindsay, A., Beacock, D., Balai, R., Kirmond, P., Brindle, P., Bundy, C., Cahill, T., Dayani, A., Eavis, P., Mohr, S., Hayne, S., Krasucki, C., Micheals, M., Orpen, I., Parker, I., Sewell, R., Sharp, D., Smith, A., Stevens, A., Upton, J., Victory, J., Wernham, C., Davis, R., Mays, C., Andrews, M., Takhar, J., Travill, C., Choudhury, P., Matta, W., Ihonor, A., O'Dong, C., Rahman, S., Singer, P., Gillam, S., Bath, P. S., Razzaq, N., O'Toole, O., Rowe, P., Williams, H., Allcock, A., Tucker, A., Sprott, V., Kyd, K., Cunliffe, G., Arden, C., Bateman, A., Kassianos, G., Sinclair, D., Turner, C., Jagathesan, R., Sattar, F., Ashford, A., Chukwu, A., Taylor, H., Pradhan, R., Rundell, T., Howlett, R., Bietzk, R., Myint, M., Partington, M., O'Reilly, F., Baverstock, M., Dixon, S., Tennekoon, M., Brand, N., Haimes, P., Keller, P., Whetstone, S., Kovyrshyna, O., Rogozhyna, V., Kiver, T., Vasylenko, V., Kucheryava, L., Salimova, S., Alekseenko, V., Gukov, O., Myhailiv, I., Kardashevskaya, L., Prikolota, O., Bashkirtcev, O., Andreev, E., Tkachenko, L., Mospan, M., Batushkin, V., Safonova, L., Ogorodnichuk, A., Pustovit, S., Romanov, S., Burlakova, L., Voloshko, Y., Lafarenko, V., Vlasuk, Z., Leshchuk, O., Chushak, S., Koval, V., Stasuk, O., Pogrebna, O., Kornienko, S., Tikhonova, S., Fesenko, T., Kuzmina, T., Ushakov, O., Vechtomova, N., Potapska, L., Illushechkin, I., Kryvenkova, E., Lysunets, O., Tsygankov, O., Bardachenko, L., Voloshyna, L., Ginzburg, V., Franskyavichene, L., Korotich, T., Vyshnevaya, N., Bilous, N., Kulinich, S., Kulik, V., Sadykova, I., Berezhna, T., Molotyagina, S., Pham, M. H., Pham, H. T., Khong, N. H., K. B., Do, T. B., Le, P. A., Do, T. C., Do, Nguyen, N. Q., Q. H., Do, K. C., Vu, Pham, N. H., Pham, T. H. T., M. C., Ta, Phan, D. P., Nguyen, T. T. H., Pham, T. T. N., T. L., To, V. T., Le, Dang, L., Bui, L., Pham, T. T. H., Phan, H. H., Bui, T. T. H., Tuong, T. V. A., Nguyen, T. P., Nguyen, T. H., Nguyen, B. K., D. B., Vu, Pham, N. S., T. Q., Do, Pham, T. S., Dang, V. D., D. T., Le, V. C., Do, Nguyen, T. K. L., Luong, H. D., Luu, T. Q., Pham, N. V., Huynh, T. K., N. T. H., Tu, Ngo, K. A., Nguyen, T. T. C., Ong, T. T. L., Doan, V. B., Kim, T. B., T. N., Vo, Tran, T. T. T., Nguyen, T. A., Tran, V. D., Nguyen, A. K., Tran, A. C., Ngo, M. H., N. H., Vu, I. T., Ly, Tran, N. P. H., Tran, L. U. P., Nguyen, T. N., Tran, T. H., Truong, P. H., Mai, T. L., Hoang, V. S., Bui, C. M. A., Dang, V. P., Truong, Q. B., M. P., Vo, Nguyen, V. T., Chau, N. H., T. T. H., Ta, Dinh, H. N., Tran, H., Nguyen, H. K. N., Chung, A., Chung, E., Martina-Hooi, B., Angela, R., Ramoutar, P., Fillet, R., Tilluckdharry, R., Dookie, T., Foster, E., Hart, C., Omardeen, F., Ramphall, S., Lalla, C., Cheng, J., Elliott, V., Falconer, H., Hurlock-Clarke, L., Ishmael, R., Lalljie, G., Lee, K., Liqui-Lung, A., Massay, R., Mohammed, H., Brown, C., Daniel, R., Didier, M., Salas, Z., CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), University of Glasgow, Maria Cecilia Hospital [Cotignola], Royal Brompton Hospital, Montreal Heart Institute Coordinating Centre (MHICC), Université de Montréal (UdeM), Medical University of Silesia (SUM), Université Paris Diderot - Paris 7 (UPD7), Laboratoire de Recherche Vasculaire Translationnelle (LVTS (UMR_S_1148 / U1148)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Dorogoichenko, Aleksandra, Laucevičius, Aleksandras, Jurgaitienė, Rūta, Šlapikas, Rimvydas, Barauskienė, Gražina, Jankauskienė, Edita, Revienė, Sigita, Vaišvila, Tautvydas, Zaronskienė, Danutė, Šlapikienė, Ona Birutė, Kupstytė, Nora, Rinkūnienė, Egidija, Steponėnienė, Rima Vitalija, Kojelienė, Jūratė, Badarienė, Jolita, Dženkevičiūtė, Vilma, Sadauskienė, Eglė, Butkuvienė, Irena, Stankevičius, R., Paliulionienė, R., Snikytė, R., Mažutavičius, R., and CLARIFY Investigators
- Subjects
Male ,Genetics and Molecular Biology (all) ,Heart disease ,medicine.medical_treatment ,atrial fibrillation ,coronary ,anticoagulants ,patients ,atrial flutter ,lcsh:Medicine ,Coronary Artery Disease ,Practice Patterns ,030204 cardiovascular system & hematology ,Chest pain ,Biochemistry ,[SHS]Humanities and Social Sciences ,Cohort Studies ,Coronary artery disease ,Angina ,0302 clinical medicine ,Aged ,Anticoagulants ,Atrial Fibrillation ,Drug Therapy, Combination ,Female ,Guideline Adherence ,Humans ,Outpatients ,Platelet Aggregation Inhibitors ,Practice Patterns, Physicians' ,Registries ,Practice Patterns, Physicians'/statistics & numerical data ,030212 general & internal medicine ,Myocardial infarction ,lcsh:Science ,Stroke ,Anticoagulants/administration & dosage ,Multidisciplinary ,Medicine (all) ,Atrial fibrillation ,Guideline Adherence/statistics & numerical data ,3. Good health ,Combination ,Cardiology ,[SHS] Humanities and Social Sciences ,medicine.symptom ,Research Article ,medicine.medical_specialty ,Coronary Artery Disease/drug therapy ,Agricultural and Biological Sciences (all) ,Biochemistry, Genetics and Molecular Biology (all) ,NO ,03 medical and health sciences ,Drug Therapy ,Internal medicine ,medicine ,Platelet Aggregation Inhibitors/administration & dosage ,Physicians' ,Atrial Fibrillation/drug therapy ,business.industry ,lcsh:R ,Percutaneous coronary intervention ,Outpatients/statistics & numerical data ,medicine.disease ,lcsh:Q ,Human medicine ,business - Abstract
BACKGROUND: Few data are available regarding the use of antithrombotic strategies in coronary artery disease patients with atrial fibrillation (AF) in everyday practice. We sought to describe the prevalence of AF and its antithrombotic management in a contemporary population of patients with stable coronary artery disease.METHODS AND FINDINGS: CLARIFY is an international, prospective, longitudinal registry of outpatients with stable coronary artery disease, defined as prior (≥12 months) myocardial infarction, revascularization procedure, coronary stenosis >50%, or chest pain associated with evidence of myocardial ischemia. Overall, 33,428 patients were screened, of whom 32,954 had data available for analysis at baseline; of these 2,229 (6.7%) had a history of AF. Median (interquartile range) CHA2DS2-VASc score was 4 (3, 5). Oral anticoagulation alone was used in 25.7%, antiplatelet therapy alone in 52.8% (single 41.8%, dual 11.0%), and both in 21.5%. OAC use was independently associated with permanent AF (pCONCLUSIONS: In this contemporary cohort of patients with stable coronary artery disease and AF, most of whom are theoretical candidates for anticoagulation, oral anticoagulants were used in only 47.2%. Half of the patients received antiplatelet therapy alone and one-fifth received both antiplatelets and oral anticoagulants. Efforts are needed to improve adherence to guidelines in these patients.TRIAL REGISTRATION: ISRCTN registry of clinical trials: ISRCTN43070564.
- Published
- 2015
5. Development of tools needed for an impact analysis for groundwater quality due to changing of agricultural soil use
- Author
-
Mioduszewski, W., Fic, M., Slesicka, A., Zdanowicz, A., Walther, W., Paetsch, M., Reinstorf, F., Weller, D., Diankov, S., Velovsky, G., Radoslavov, S., Marinov, W., Nicheva, O., Querner, E.P., and Roelsma, J.
- Subjects
Alterra - Centre for Water and Climate ,Life Science ,Wageningen Environmental Research ,Alterra - Centrum Water en Klimaat - Published
- 2005
6. Hepatitis C virus 5′ untranslated region variability correlates with treatment outcome
- Author
-
Bukowska-Ośko, I., primary, Radkowski, M., additional, Pawełczyk, A., additional, Rosinska, M., additional, Caraballo Cortés, K., additional, Płoski, R., additional, Berak, H., additional, Horban, A., additional, Stanczak, J., additional, Fic, M., additional, and Laskus, T., additional
- Published
- 2013
- Full Text
- View/download PDF
7. Variability of hepatitis C virus hypervariable region 1 (HVR-1) during the early phase of pegylated interferon and ribavirin therapy.
- Author
-
Cortós, K. Caraballo, Laskus, T., Bukowska-Osśko, I., Pawełczyk, A., Berak, H., Horban, A., Fic, M., and Radkowski, M.
- Subjects
HEPATITIS C virus ,VIRAL genetics ,INTERFERONS ,RIBAVIRIN ,POLYMERASE chain reaction ,GENETIC polymorphisms - Abstract
Purpose: Genetic variability of hepatitis C virus (HCV) is considered to be an important factor defining viral pathogenesis, [persistence and resistance to treatment. The aim of the present study was to characterize HCV genetic heterogeneity within a hypervariable region 1 (HVR-1) before and during the early period of pegylated interferon alfa (PEG-IFN-α) and ribavirin treatment in correlation with treatment outcome. Material and Methods: The study involved 24 patients treated with PEG-IFN-α and ribavirin whose sera were collected before (baseline) and at 7,14, 21 28 and 56 day of treatment. HCV HVR-1 region was amplified by nested RT-PCR and subjected to SSCP (single strand conformational polymorphism) analysis. SSCP changes of HCV HVR-1 over time in each patient were : compared to treatment outcome results. Results: In 2/11 (18%) SVR+ and 8/13 (62%) SVR- treated patients, HVR-1 genetic changes manifested by new SSCP bands (new genetic variants) and were significantly more frequent in nonresponders (P <0.05). Conclusions: Our results indicate that HCV HVR-1 variability during the early phase of PEG-IFN-α and ribavirin therapy may be predictive of treatment outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
8. An analysis of HCV nonstructural NS3 protein expression in bone marrow cells of HCV-infected patients with hematological disorders
- Author
-
Agnieszka Pawełczyk, Polańska, M., Kisiel, E., Chmielewski, M., Bukowska, I., Cortes, K. C., Fic, M., Warzocha, K., and Radkowski, M.
9. Replication of HCV in bone marrow of patients with haematological disorders,Replikacja wirusa zapalenia watroby typu C (HCV) w szpiku kostnym pacjentów z zaburzeniami hematologicznymi
- Author
-
Agnieszka Pawełczyk, Polańska, M., Kisiel, E., Chmielewski, M., Bukowska, I., Fic, M., and Radkowski, M.
10. Serum and PBMC 5′ UTR HCV quasispecies changes in a patient with chronic hepatitis type C treated with interferon and ribavirin
- Author
-
Bukowska, I., Cortes, K. C., Berak, H., Agnieszka Pawełczyk, Chmielewski, M., Polańska, M., Fic, M., Horban, A., and Radkowski, M.
11. [Comparison of 5'UTR and HVR1 of hepatitis c virus (HCV) in serum and peripheral blood mononuclear cells in the early phase of interferon and ribavirin treatment].,Analiza porównawcza regionu 5'UTR oraz HVR1 wirusa zapalenia watroby typu C (HCV) w surowicy i komorkach jednojadrzastych krwi obwodowej (PBMC) we wczesnej fazie leczenia interferonem i rybawiryna
- Author
-
Cortés, K. C., Ośko, I., Agnieszka Pawełczyk, Berak, H., Fic, M., Horban, A., and Radkowski, M.
12. Replication analysis of hepatitis G virus (HGV)/GBV-C in bone marrow of patients with B-cell lymphoproliferative disorders and Hodgkin's disease
- Author
-
Kisiel, E., Agnieszka Pawełczyk, Chmielewski, M., Cortes, K. C., Bukowska, I., Fic, M., Centkowski, P., Warzocha, K., and Radkowski, M.
13. Valve exploiting the principle of a side channel turbine
- Author
-
Jandourek Pavel, Habán Vladimír, Pochylý František, and Fic Miloslav
- Subjects
Physics ,QC1-999 - Abstract
The article deals with a side channel turbine, which can be used as a suitable substitute for a pressure reducing valve. Reducing valves are a source of hydraulic losses. The aim is to replace them by a side channel turbine. With that in mind, hydraulic losses can be replaced by a production of electrical energy at comparable characteristics of the valve and the turbine. The basis for the design is the loss characteristics of the valve. Thereby creating a kind of turbine valve with speed-controlled flow in dependence of runner revolution.
- Published
- 2017
- Full Text
- View/download PDF
14. Clinical Trial: A Pragmatic Randomised Controlled Study to Assess the Effectiveness of Two Patient Management Strategies in Mild to Moderate Ulcerative Colitis-The OPTIMISE Study.
- Author
-
Danese S, Fiorino G, Vicaut E, Paridaens K, Ugur A, Clark B, Vanasek T, Stepek D, D'Amico F, West R, Gilissen LPL, Wisniewska Jarosinka M, Drobinski P, Fronik G, Fic M, Walczak M, Kowalski M, Korczowski B, Wiatr M, and Peyrin-Biroulet L
- Abstract
Background: Current management of mild-to-moderate ulcerative colitis (UC) involves monitoring clinical markers of disease activity, such as stool frequency (SF) and rectal bleeding (RB), and adjusting treatment accordingly. Our aim was to assess whether targeting treatment based on faecal calprotectin (FC) levels (treat-to-target; T2T) provides greater UC disease control versus a symptom-based approach. Methods: This was a pragmatic, randomised (1:1) controlled study of patients with mild-to-moderate UC (global Mayo score 2-6) treated with ≤2.4 g/day 5-aminosalicylic acid that compared the effectiveness of two management strategies with (interventional arm) and without (reference arm) FC home monitoring over 12 months of follow-up. Treatment was optimised in the interventional arm using FC values and clinical symptoms (PRO-2), while the reference arm used only PRO-2. Results: 193 patients completed the study. No significant difference was found for the primary endpoint (Mayo Endoscopic Subscore [MES] = 0 at 12 months). A numerical advantage for the interventional arm over the reference arm for the primary endpoint (37.0% vs. 33.4%, respectively) and for MES ≤ 1, RB = 0, and SF ≤ 1 at 12 months was found following imputation for missing data. The composite endpoint of MES = 0, RB = 0, and SF ≤ 1 at 12 months was achieved at a significantly higher rate in the interventional arm than the reference arm (effect size [ES]: 0.17, 95% CI 0.02-0.32; p < 0.05). A similar result was obtained for MES ≤ 1, RB = 0 and SF ≤ 1 (ES: 0.22; 95% CI 0.07-0.37; p < 0.05). Conclusions: T2T using FC monitoring was effective in patients with mild-to-moderate UC at 12 months. Further longer-term studies are required to confirm the results.
- Published
- 2024
- Full Text
- View/download PDF
15. Therapeutic methods of gut microbiota modification in colorectal cancer management - fecal microbiota transplantation, prebiotics, probiotics, and synbiotics.
- Author
-
Kaźmierczak-Siedlecka K, Daca A, Fic M, van de Wetering T, Folwarski M, and Makarewicz W
- Subjects
- Animals, Colorectal Neoplasms microbiology, Combined Modality Therapy, Humans, Colorectal Neoplasms therapy, Fecal Microbiota Transplantation, Gastrointestinal Microbiome, Prebiotics administration & dosage, Probiotics administration & dosage, Synbiotics administration & dosage
- Abstract
The link between gut microbiota and the development of colorectal cancer has been investigated. An imbalance in the gut microbiota promotes the progress of colorectal carcinogenesis via multiple mechanisms, including inflammation, activation of carcinogens, and tumorigenic pathways as well as damaging host DNA. Several therapeutic methods are available with which to alter the composition and the activity of gut microbiota, such as administration of prebiotics, probiotics, and synbiotics; these can confer various benefits for colorectal cancer patients. Nowadays, fecal microbiota transplantation is the most modern way of modulating the gut microbiota. Even though data regarding fecal microbiota transplantation in colorectal cancer patients are still rather limited, it has been approved as a clinical method of treatment-recurrent Clostridium difficile infection, which may also occur in these patients. The major benefits of fecal microbiota transplantation include modulation of immunotherapy efficacy, amelioration of bile acid metabolism, and restoration of intestinal microbial diversity. Nonetheless, more studies are needed to assess the long-term effects of fecal microbiota transplantation. In this review, the impact of gut microbiota on the efficiency of anti-cancer therapy and colorectal cancer patients' overall survival is also discussed.
- Published
- 2020
- Full Text
- View/download PDF
16. Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases.
- Author
-
Kaźmierczak-Siedlecka K, Ruszkowski J, Fic M, Folwarski M, and Makarewicz W
- Subjects
- Diarrhea, Humans, Helicobacter Infections, Helicobacter pylori, Probiotics, Saccharomyces boulardii
- Abstract
The yeast Saccharomyces boulardii CNCM I-745 is a unique, non-bacterial microorganism classified as a probiotic agent. In this review article, at first, we briefly summarized the mechanisms responsible for its probiotic properties, e.g. adhesion to and elimination of enteropathogenic microorganisms and their toxins; extracellular cleavage of pathogens' virulent factors; trophic and anti-inflammatory effects on the intestinal mucosa. The efficacy of S. boulardii administration was tested in variety of human diseases. We discussed the results of S. boulardii CNCM I-745 use in the treatment or prevention of Helicobacter pylori infections, diarrhoea (Clostridium difficile infections, antibiotic-associated diarrhoea, and traveller's diarrhoea), inflammatory bowel diseases, irritable bowel syndrome, candidiasis, dyslipidemia, and small intestine bacterial overgrowth in patients with multiple sclerosis. In case of limited number of studies regarding this strain, we also presented studies demonstrating properties and efficacy of other strains of S. boulardii. Administration of S. boulardii CNCMI I-745 during antibiotic therapy has certain advantage over bacterial probiotics, because-due to its fungal natural properties-it is intrinsically resistant to the antibiotics and cannot promote the spread of antimicrobial resistance. Even though cases of fungemia following S. boulardii CNCM I-745 administration were reported, it should be treated as a widely available and safe probiotic strain.
- Published
- 2020
- Full Text
- View/download PDF
17. The Impact of Melatonin on Colon Cancer Cells' Resistance to Doxorubicin in an in Vitro Study.
- Author
-
Fic M, Gomulkiewicz A, Grzegrzolka J, Podhorska-Okolow M, Zabel M, Dziegiel P, and Jablonska K
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Member 1 genetics, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cell Line, Tumor, Colonic Neoplasms drug therapy, Colonic Neoplasms metabolism, Doxorubicin therapeutic use, Gene Expression Regulation, Neoplastic, Humans, Melatonin metabolism, ATP Binding Cassette Transporter, Subfamily B, Member 1 drug effects, Colonic Neoplasms physiopathology, Drug Resistance, Multiple drug effects, Drug Resistance, Neoplasm drug effects, Melatonin therapeutic use
- Abstract
Multi-drug resistance (MDR) is the main cause of low effectiveness of cancer chemotherapy. P-glycoprotein (P-gp) is one of the main factors determining MDR. Some studies indicate the potential role of melatonin (MLT) in MDR. In this study, we examined the effect of MLT on colon cancer cell's resistance to doxorubicin (DOX). Using the sulforhodamine B (SRB), method the effect of tested substances on the survival of LoVo (colon cancer cells sensitive to DOX) and LoVo
DX (colon cancer cells resistant to DOX) was rated. Using immunocytochemistry (ICC), the expression of P-gp in the LoVo and LoVoDX was determined. With the real-time PCR (RT-PCR) technique, the ABCB1 expression in LoVoDX was evaluated. Based on the results, it was found that MLT in some concentrations intensified the cytotoxicity effect of DOX in the LoVoDX cells. In the ICC studies, it was demonstrated that certain concentrations of MLT and DOX cause an increase in the percentage of cells expressing P-gp, which correlates positively with ABCB1 expression ( RT-PCR). The mechanism of overcoming resistance by MLT is probably not only associated with the expression of P-gp. It seems appropriate to carry out further research on the use of MLT as the substance supporting cancer chemotherapy., Competing Interests: The authors declare no conflict of interest.- Published
- 2017
- Full Text
- View/download PDF
18. Viral etiologies in adult patients with encephalitis in Poland: A prospective single center study.
- Author
-
Popiel M, Perlejewski K, Bednarska A, Dzieciątkowski T, Paciorek M, Lipowski D, Jabłonowska M, Czeszko-Paprocka H, Bukowska-Ośko I, Caraballo Cortes K, Pawełczyk A, Fic M, Horban A, Radkowski M, and Laskus T
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Poland, Prospective Studies, Young Adult, Encephalitis, Viral virology
- Abstract
Encephalitis is a severe neurological syndrome associated with high morbidity and mortality as well as long-term neurological sequelae. Despite being an important public health problem, very few extensive population-based studies were conducted so far in the world and none in Central Europe. Altogether 114 consecutive patients meeting the initial criteria for encephalitis were enrolled at the Warsaw Hospital for Infectious Diseases between June 2012 and July 2015. Eighteen patients were secondarily excluded from the analysis due to incomplete data or noinfectious cause. Potential pathogen sequences were searched for by molecular methods in the cerebrospinal fluid (CSF) and specific antibodies were detected in CSF and sera. An infectious agent was identified in 41 patients (42.7%). The most frequently diagnosed infections were Human herpesvirus 1 (HHV-1) (22 cases, 24%) followed by Enterovirus (6 cases, 6.3%), Varicella zoster virus (VZV) (5 cases, 5.2%), Tick-borne encephalitis virus (TBEV) (6 cases, 6.3%) and Cytomegalovirus (CMV) (2 cases, 2.1%). There were no cases of human adenovirus, Human herpesvirus 6 (HHV-6) or West Nile virus (WNV) infection identified. In 55 cases (57.3%) the cause of encephalitis remained unknown. Compared to patients in whom the diagnosis was determined the latter group contained more women, was less likely to manifest fever and had lower CSF pleocytosis (p < 0.05) In summary, we identified HHV-1 followed by Enterovirus, VZV and TBEV as the most common causes of encephalitis among adult patients in Poland. In a large proportion of patients the cause of encephalitis remained unknown.
- Published
- 2017
- Full Text
- View/download PDF
19. Genetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin.
- Author
-
Bukowska-Ośko I, Pawełczyk A, Perlejewski K, Kubisa N, Caraballo Cortés K, Rosińska M, Płoski R, Fic M, Kaźmierczak J, Popiel M, Ząbek P, Horban A, Radkowski M, and Laskus T
- Subjects
- Adult, Antiviral Agents pharmacology, Antiviral Agents therapeutic use, Base Sequence, Female, HIV drug effects, Hepacivirus drug effects, Humans, Interferon-alpha pharmacology, Interleukins genetics, Male, Middle Aged, Molecular Sequence Data, Polymorphism, Single-Stranded Conformational genetics, Ribavirin pharmacology, Sequence Alignment, Treatment Outcome, Young Adult, 5' Untranslated Regions genetics, Coinfection drug therapy, Coinfection virology, Genetic Variation, HIV genetics, Hepacivirus genetics, Interferon-alpha therapeutic use, Ribavirin therapeutic use
- Abstract
Association between hepatitis C virus (HCV) quasispecies and treatment outcome among patients with chronic hepatitis C has been the subject of many studies. However, these studies focused mainly on viral variable regions (E1 and E2) and usually did not include human immunodeficiency virus (HIV)-positive patients. The aim of the present study was to analyze heterogeneity of the 5' untranslated region (5'UTR) in HCV/HIV coinfected patients treated with interferon and ribavirin. The HCV 5'UTR was amplified from serum and peripheral blood mononuclear cells (PBMC) samples in 37 HCV/HIV coinfected patients treated for chronic hepatitis C. Samples were collected right before treatment, and at 2, 4, 6, 8, 12, 20, 24, 36, 44, 48, 60, and 72 weeks. Heterogeneity of the 5'UTR was analyzed by single strand conformational polymorphism (SSCP), cloning and sequencing. Sustained virological response (SVR) was achieved in 46% of analyzed HCV/HIV co-infected patients. Stable SSCP band pattern was observed in 22 patients (62.9%) and SVR rate among these patients was 23%. Decline in the number of bands and/or shift in band positions were found in 6 patients (17.1%), 5 (83%) of whom achieved SVR (p=0.009). A novel viral genotype was identified in all but one of these patients. In 5 of these 6 patients a new genotype was dominant. 5'UTR heterogeneity may correlate with interferon and ribavirin treatment outcome. In the analyzed group of HCV/HIV coinfected patients, viral quasispecies stability during treatment favored viral persistence, whereas decrease in the number of variants and/or emergence of new variants was associated with SVR. Among injection drug users (IDU) patients, a new genotype may become dominant during treatment, probably due to the presence of mixed infections with various strains, which have different susceptibility to treatment.
- Published
- 2015
- Full Text
- View/download PDF
20. Analysis of genotype 1b hepatitis C virus IRES in serum and peripheral blood mononuclear cells in patients treated with interferon and ribavirin.
- Author
-
Bukowska-Ośko I, Caraballo Cortés K, Pawełczyk A, Płoski R, Fic M, Perlejewski K, Demkow U, Berak H, Horban A, Laskus T, and Radkowski M
- Subjects
- 5' Untranslated Regions, Adult, Aged, Female, Humans, Male, Middle Aged, Viral Tropism drug effects, Viral Tropism genetics, Antiviral Agents administration & dosage, Genotype, Hepacivirus genetics, Hepatitis C drug therapy, Hepatitis C genetics, Interferon-alpha administration & dosage, Leukocytes, Mononuclear virology, Point Mutation, RNA, Viral genetics, Regulatory Sequences, Ribonucleic Acid genetics, Ribavirin administration & dosage
- Abstract
Hepatitis C virus (HCV) highly conserved IRES (internal ribosome entry site) sequence, localized within the 5(')-untranslated region (5(')UTR), may determine viral properties like replication efficiency and cell tropism. The aim of the present study was to characterize newly emerging 5(')UTR variants in serum and peripheral blood mononuclear cells (PBMC) in chronic hepatitis C patients treated with interferon (IFN) and ribavirin and to identify their effect on IRES secondary structures. The study group consisted of 87 patients infected with genotype 1b from whom serum and PBMC samples were collected at 9 time points (before, during, and after treatment). New 5(')UTR variants developed in 9 patients. Out of the overall 14 new variants, 9 (64%) were found in PBMC. HCV variants with decreased thermodynamic stability were identified only in PBMC and C183U mutation was the most common one in this compartment. In conclusion, antiviral treatment may favor emergence of new 5(')UTR variants both in blood and in PBMC compartments. However, variants developing in the latter compartment were predicted to have lower thermodynamic stability of the IRES secondary structures compared to serum strains. C-U change in position 183, which has not been described previously, might indicate viral adaptation to lymphoid cells.
- Published
- 2014
- Full Text
- View/download PDF
21. Hepatitis C virus (HCV) infection of peripheral blood mononuclear cells in patients with type II cryoglobulinemia.
- Author
-
Jabłońska J, Ząbek J, Pawełczyk A, Kubisa N, Fic M, Laskus T, and Radkowski M
- Subjects
- Aged, Antigens, CD19 metabolism, B-Lymphocyte Subsets metabolism, B-Lymphocyte Subsets virology, CD3 Complex metabolism, Cryoglobulinemia immunology, Female, Hepacivirus immunology, Hepacivirus metabolism, Hepatitis C, Chronic immunology, Humans, Leukocytes, Mononuclear immunology, Lipopolysaccharide Receptors metabolism, Male, Middle Aged, Monocytes immunology, Monocytes metabolism, T-Lymphocyte Subsets metabolism, T-Lymphocyte Subsets virology, Cryoglobulinemia complications, Cryoglobulinemia virology, Hepatitis C, Chronic complications, Hepatitis C, Chronic virology, Leukocytes, Mononuclear virology
- Abstract
Objectives: Type II cryoglobulinemia is a common extrahepatic manifestation of chronic hepatitis C virus (HCV) infection. The mechanisms behind its development are unclear, but could be related to direct infection of the immune cells., Methods: Peripheral blood mononuclear cells from 18 patients with type II cryoglobulinemia were separated into CD3+ (T cells), CD19+ (B cells) and CD14+ (monocytes) and analyzed for the presence of negative strand HCV RNA, which is a viral replicative intermediate, and for the presence of HCV non-structural protein 3 (NS3). Control group consisted of 182 consecutive chronic hepatitis C patients prior to initiation of antiviral therapy., Results: Negative strand HCV RNA was detected in PBMC from six (33.3%), patients and in 15 (8.2%) controls (p < 0.01). Negative strand was most frequently detected in B cells (3 patients), followed by T cells (2 patients), and monocytes (2 patients). One patient was positive both in CD3+ and CD14+ cells. NS3 protein was detected in six (33.3%) patients; five were positive in T cells, three in B cells, and another three were positive in monocytes. Two patients were positive in all analyzed cell subpopulation and one patient was positive in CD14+ and CD19+ cells, but not in CD3+ cells. Altogether, 11 patients (61.1%) were positive either for the negative strand HCV RNA or NS3 protein in at least one of the analyzed cell compartments., Conclusion: Our findings of common presence of viral replication in cells of the immune system suggest that direct HCV infection could play a role in the etiology of cryoglobulinemia., (Copyright © 2013 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
22. Detection of hepatitis C virus (HCV) negative strand RNA and NS3 protein in peripheral blood mononuclear cells (PBMC): CD3+, CD14+ and CD19+.
- Author
-
Pawełczyk A, Kubisa N, Jabłońska J, Bukowska-Ośko I, Caraballo Cortes K, Fic M, Laskus T, and Radkowski M
- Subjects
- Adult, Aged, Blood virology, Female, Hepacivirus chemistry, Hepacivirus genetics, Humans, Immunohistochemistry, Leukocytes, Mononuclear chemistry, Male, Middle Aged, RNA, Viral genetics, Reverse Transcriptase Polymerase Chain Reaction, Virus Replication, Antigens, CD19 analysis, CD3 Complex analysis, Hepacivirus physiology, Leukocytes, Mononuclear virology, Lipopolysaccharide Receptors analysis, RNA, Viral analysis, Viral Nonstructural Proteins analysis
- Abstract
Background: Although hepatitis C virus (HCV) is primarily hepatotropic, markers of HCV replication were detected in peripheral blood mononuclear cells (PBMC) as well as in ex vivo collected tissues and organs. Specific strains of HCV were found to be capable to infect cells of the immune system: T and B cells and monocytes/macrophages as well as cell lines in vitro. The direct invasion of cells of the immune system by the virus may be responsible for extrahepatic consequences of HCV infection: cryoglobulinemia and non-Hodgkin's lymphoma.The aim of the present study was to determine the prevalence of markers of HCV infection: negative strand HCV RNA and non-structural NS3 protein in PBMC subpopulations: CD3+, CD14+ and CD19+. The presence of virus and the proportion of affected cells within a particular PBMC fraction could indicate a principal target cell susceptible for HCV., Methods: PBMC samples were collected from 26 treatment-free patients chronically infected with HCV. PBMC subpopulations: CD3+, CD14+, CD19+ were obtained using positive magnetic separation. The presence of negative strand RNA HCV and viral NS3 protein were analyzed by strand-specific RT-PCR and NS3 immunocytochemistry staining., Results: Negative strand HCV RNA was detectable in 7/26 (27%), whereas NS3 protein in 15/26 (57.6%) of PBMC samples. At least one replication marker was found in 13/26 (50%) of CD3+ cells then in 8/26 (30.8%) of CD14+ and CD19+ cells. The highest percentage of cells harboring viral markers in single specimen was also observed in CD3+ (2.4%), then in CD19+ (1.2%), and much lower in CD14+ (0.4%) cells., Conclusions: Our results indicate that CD3+ cells are a dominant site for extrahepatic HCV replication, although other PBMC subpopulations may also support virus replication.
- Published
- 2013
- Full Text
- View/download PDF
23. [Comparison of 5'UTR and HVR1 of hepatitis c virus (HCV) in serum and peripheral blood mononuclear cells in the early phase of interferon and ribavirin treatment].
- Author
-
Cortés KC, Ośko I, Pawełczyk A, Berak H, Fic M, Horban A, and Radkowski M
- Subjects
- Antiviral Agents therapeutic use, Drug Therapy, Combination, Hepatitis C, Chronic blood, Humans, Interferon alpha-2, Interferon-alpha therapeutic use, Poland, Polymorphism, Single-Stranded Conformational, Recombinant Proteins, Ribavirin therapeutic use, Sequence Alignment, Genetic Variation, Hepacivirus drug effects, Hepacivirus genetics, Hepatitis C, Chronic drug therapy, Viral Envelope Proteins drug effects, Viral Envelope Proteins genetics
- Abstract
Genetic heterogeneity is a characteristic feature of hepatitis C virus (HCV) and it reflects selection mechanisms affecting the virus. It is considered a major factor contributing the viral persistence and drug resistance. The following work presents the preliminary results of 5'UTR and E2/HVR1 genetic variation analysis and comparison in serum and peripheral blood mononuclear cells (PBMC) of 7 patients before and during the early phase of pegylated interferon alfa (PEG-IFN-alpha) and ribavirin therapy. Single strand conformational polymorphism (SSCP) analysis revealed genetic stability of 5'UTR in all but one patient who did not respond to treatment (SVR-), where new genetic variants appeared. E2/HVR1 genetic changes were characteristic in patients displaying treatment failure (SVR-) and usually reflected fluctuations in complexity and appearance of new genetic HCV variants. Genetic changes (reduction in complexity) were found in one of three sustained virological responders (SVR+ patients). Comparatory analysis of the HCV quasispecies present in serum and PBMC showed differences in at least one analysed region in all non-responders. Presented results suggest the independent forces driving genetic changes in analysed regions. They also point out the presence of genetic compartmentalization possibly having an impact on antiviral treatment result.
- Published
- 2011
24. [Replication of HCV in bone marrow of patients with haematological disorders].
- Author
-
Pawełczyk A, Polańska M, Kisiel E, Chmielewski M, Bukowska I, Fic M, and Radkowski M
- Subjects
- Bone Marrow Cells virology, Female, Hemophilia A virology, Hepatitis C complications, Humans, Leukemia, Myeloid, Acute virology, Lymphoma virology, Male, Pancytopenia virology, Poland, RNA, Viral analysis, Bone Marrow virology, Hematologic Diseases virology, Hepacivirus physiology, Hepatitis C diagnosis, Leukocytes, Mononuclear virology, Virus Replication
- Abstract
Unlabelled: The aim of the study was to evaluate the presence of HCV replication in bone marrow cells derived from patients displaying hematological disorders. We analysed serum, peripheral blood mononuclear cells (PBMC) and bone marrow samples obtained from 27 patients displaying the following dysfunctions: lymphoma, trombocytopenia, haemophilia, pancytopenia and acute myeloid leukemia (AML). The presence of HCV-RNA in samples was detected by RT-PCR. All the serum samples were HCV-RNA positive as well as 9 out of 27 (33%) PBMC and 17 out of 27 (63%) of bone marrow samples. Independently to the disorder type, the co-presence of HCV-RNA in serum and bone marrow with the simultaneous absence of the viral genetic material in PBMC was detected in 5 (18.5%) of patients. This result suggests that bone marrow is a site of active viral replication. To check whether a viral replication generates any mutations, an SSCP analysis of the 5'UTR viral region was performed. The difference in the viral sequence derived from serum, PBMC and bone marrow was detected in one case. This result may indicate the occurrence of mutation process during the viral replication in bone marrow. An immunohistochemical analysis of bone marrow smears showed the presence of HCV antigens., Conclusion: bone marrow cells of patients displaying hematological disorders represent a putative site of extrahepatic HCV replication.
- Published
- 2009
25. Effect of melatonin on cytotoxicity of doxorubicin toward selected cell lines (human keratinocytes, lung cancer cell line A-549, laryngeal cancer cell line Hep-2).
- Author
-
Fic M, Podhorska-Okolow M, Dziegiel P, Gebarowska E, Wysocka T, Drag-Zalesinska M, and Zabel M
- Subjects
- Apoptosis drug effects, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung pathology, Cell Line, Tumor, Cell Survival drug effects, Comet Assay, DNA Damage, Dose-Response Relationship, Drug, Drug Combinations, Drug Screening Assays, Antitumor, Humans, Keratinocytes pathology, Laryngeal Neoplasms drug therapy, Laryngeal Neoplasms pathology, Lung Neoplasms drug therapy, Lung Neoplasms pathology, Necrosis, Respiratory Tract Neoplasms pathology, Antineoplastic Agents pharmacology, Antioxidants pharmacology, Doxorubicin pharmacology, Keratinocytes drug effects, Melatonin pharmacology, Respiratory Tract Neoplasms drug therapy
- Abstract
The pineal hormone melatonin (MLT) has been recognised as a substance capable of alleviating in vivo nephro-, cardio- and myelotoxicity of doxorubicin (DOX) and of other anthracyclines in animal models. However, few data are available on the effects of MLT on cytotoxicity of antineoplastic drugs toward tumor cells in vitro. The present study aimed at the evaluation of effects of MLT and of DOX on selected cell lines. The experiments were conducted on human keratinocytes (primary culture), non-small cell lung cancer (A-549) and laryngeal cancer cell lines (HEp-2). In keratinocytes and in A-549 cells, MLT used at pharmacological concentrations (0.1 and 1.0 mM) was observed to intensify apoptotic lesions. MLT exerted no clear-cut effects on the HEp-2 cell line. In contrast, DOX at concentrations of 0.1 and 1.0 microg/ml intensified apoptosis and augmented the frequency of necrotic lesions in cell nuclei in all the examined cell lines. MLT intensified cytotoxicity of DOX in all cell lines, significantly decreasing cell numbers and promoting apoptosis. The effect was MLT concentration-dependent. MLT decreased the proportion of cells with necrotic lesions.
- Published
- 2007
26. Coexpression of CD1a, langerin and Birbeck's granules in Langerhans cell histiocytoses (LCH) in children: ultrastructural and immunocytochemical studies.
- Author
-
Dziegiel P, Dolilńska-Krajewska B, Dumańska M, Wecławek J, Jeleń M, Podhorska-Okołów M, Jagoda E, Fic M, and Zabel M
- Subjects
- Adolescent, Antigens, CD1 immunology, Child, Preschool, Cytoplasmic Granules ultrastructure, Female, Histiocytosis, Langerhans-Cell pathology, Humans, Infant, Infant, Newborn, Langerhans Cells ultrastructure, Male, Antigens, CD metabolism, Antigens, CD1 metabolism, Histiocytosis, Langerhans-Cell diagnosis, Immunohistochemistry, Langerhans Cells immunology, Lectins, C-Type metabolism, Mannose-Binding Lectins metabolism
- Abstract
Langerhans cell histiocytoses (LCH) represent rare diseases of unclear etiology and pathogenesis. Most of the cases include children, 1 to 15 years of age, and various organs are involved (bones, skin, liver, lymph nodes, bone marrow and other). The diagnosis of LCH used to be established by biopsy of the inflamed tissue and demonstration of expression of markers specific for Langerhans cells: CD1a and langerin. The diagnosis can be ultimately confirmed by demonstration of Birbeck's granules in the electron microscopy. The present study was aimed at immunocytochemical demonstration, in the examined LCH material (skin, bones, lymph nodes), of the specific antigen expression and at comparing it with the presence of Birbeck's granules. In the examined 11 cases co-expression of CD1a with langerin and with the presence of Birbeck's granules was noted. Also in all examined biopsies the expression of S-100 protein on inflammatory cells was found. The results corroborate the usefulness of immunocytochemical studies on CD 1 a and langerin expression in diagnosis of LCH.
- Published
- 2007
27. [Hepatitis B virus DNA polymerase].
- Author
-
Łoch T, Pawińska-Zdziebłowska A, and Fic MH
- Subjects
- Carrier State metabolism, Hepatitis B e Antigens blood, Hepatitis B, Chronic enzymology, Hepatitis B, Chronic genetics, Humans, DNA-Directed DNA Polymerase blood, Hepatitis B virus enzymology, Hepatitis B virus genetics, Hepatitis B, Chronic metabolism
- Abstract
Our aim was to discuss the practical value of HBV DNA polymerase (DNAp) determination. DNAp activity is a good marker of HBV high replication in patients with chronic hepatitis B (HBeAg+), very useful during monitoring of immunostimulation and/or antiviral treatment.
- Published
- 2001
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.